Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. - Wikidata - awgldk - TriplyDB

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

http://www.wikidata.org/entity/Q43556824

about

Emerging drugs for Guillain-Barré syndrome Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis Systematic reviews of treatment for inflammatory demyelinating neuropathy Amplification of autoimmune disease by infection Acute lung failure Update on Guillain-Barré syndrome Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome.Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases Acute paretic syndrome in juvenile White Leghorn chickens resembles late stages of acute inflammatory demyelinating polyneuropathies in humans.Seasonal and monthly trends in the occurrence of Guillain-Barre syndrome over a 5-year period: A tertiary care hospital-based study from South India.Detection of Campylobacter jejuni by culture and real-time PCR in a French cohort of patients with Guillain-Barre syndrome.Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope.Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.Campylobacter jejuni infection during pregnancy: long-term consequences of associated bacteremia, Guillain-Barré syndrome, and reactive arthritist.Early recognition of poor prognosis in Guillain-Barre syndrome Advances in the management of Guillain-Barré syndrome.Fcγ receptor-mediated inflammation inhibits axon regeneration.Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases Analysis of the activity and regulon of the two-component regulatory system composed by Cjj81176_1484 and Cjj81176_1483 of Campylobacter jejuni.Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.Miller Fisher syndrome linked to Norovirus infection.Guillain-Barré syndrome, greater Paris area.Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome Characterization of two putative cytochrome c peroxidases of Campylobacter jejuni involved in promoting commensal colonization of poultry.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Orthopaedic manifestations and diagnostic clues in children with Guillain-Barré syndrome.Prediction of Functional Outcome in Axonal Guillain-Barre Syndrome.Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.Clinical Heterogeneity of Guillain-Barré Syndrome in the Emergency Department: Impact on Clinical Outcome.Acute generalized weakness in patients referred to Amirkola Children's Hospital from 2005 to 2010.Low-affinity Fcgamma receptors, autoimmunity and infection.Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?Infections and vaccinations preceding childhood Guillain-Barré syndrome: a prospective study.Recent developments and future directions in Guillain-Barré syndrome.Guillain-Barré Syndrome in a Boy With Lung Fluke Infection: Case Report and Literature Review.T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity.

P2860

Q22241376-2B80C9C9-5BCC-4AA8-9D93-DE5A9E47F1DB Q22251013-69E317DF-6555-4211-9DF3-CB3B87265C22 Q24676037-62491532-8E2B-4189-B868-94038617DF15 Q24804390-122DF106-F71D-4313-871C-2971E799D421 Q26852173-41A783F3-521A-4007-86A3-2D350288DE95 Q28293098-8B652CD1-D0B5-4006-9BB3-3D71C38A6B34 Q28477706-75927E79-BE3C-4316-8BE6-EEFE3982B60E Q30524065-584510A5-911A-4819-AA55-3F3EEF9EEB26 Q30809956-7FD1F499-A7D2-44DE-9441-245F33BE1B19 Q31123673-69DC3F6C-E3F3-4069-86C5-253BBADFD04C Q33672114-E2C394D1-8BC1-4B30-B4A3-4A0BAED129F6 Q33877878-00C3839F-CC01-465F-9130-7597C0819462 Q33909538-5D77084E-78EC-4872-BE99-2E7BC5D795C1 Q34130499-A78C4113-FA36-41C0-8AF3-75D09C02E37E Q34451654-A8B25C9E-A254-4EC9-98A5-7C390A356F07 Q34556837-06FC9B33-32EF-4B3E-AF36-5169B8364DBD Q34600024-59BB9443-785A-4AE6-9795-0EE0A5672D19 Q34686090-A4494687-CC3A-43E0-A467-917A9FDCBE80 Q34929493-17332EE4-FBD3-4AC5-98B7-8C6071002EA0 Q35093733-1CF9F3B4-4ACE-45A9-8C23-85A0854B5BF6 Q35220367-752AB7E9-D2A4-4709-8111-60D6979BEAEA Q35490901-8F33DC0D-254B-4844-9881-FDFD4959BB0A Q35705601-14AB4076-CA60-4BEA-844B-37C4B01E25FE Q35842193-F33775BE-85EC-4DCA-9D2D-E63F2A3F263A Q35982640-8D42173B-6525-46EA-B8B8-8CF114ED5C13 Q36026122-E5AAEFD8-D329-4D3B-9F6B-84FC539386AC Q36153916-D86BCCFF-B1E2-4308-9F98-040FF1E8F691 Q36483527-B6431437-4C9F-43B6-BE56-1733F4381534 Q36882923-CBDD5C57-63CF-4CFA-B18E-18E4DBD7C4B0 Q36902349-FB6022A9-FB32-4AF8-99EF-F642CFF7ADB5 Q37109992-F022CB30-B958-4B78-9AF6-1133303A70FF Q37207391-4BC7AFF8-5568-4FC0-86BA-BE7B96958870 Q37330060-214ACFAB-C294-4522-BAD5-CF0692D06F53 Q37389396-0D19766D-2D2C-478E-87E7-FD71FA09A971 Q37578785-9C441583-6EF1-4687-B010-62F037EF9106 Q37782118-459B7A1A-765E-4F62-BB7F-FEBA3CC41C1F Q37862292-1A16C056-162F-4F0A-A3FC-91959AF70BD8 Q38070887-78D69797-1E02-439D-8D0E-97863C4181CC Q38254018-E1065DD4-42C7-491A-A4E8-84D6F89C018C Q38640293-0114C5A4-24C8-49A9-8C9E-993D69BDAF41

P2860

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

http://www.wikidata.org/entity/Q43556824

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@en

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@nl

type

label

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@en

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@nl

prefLabel

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@en

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@nl

P1433

Q43556824-3041A994-4A81-424E-83BC-A22F0D6339A9

P1476

Q43556824-D1F74E3E-B606-4D38-8DE5-52E6EFB52615

P2093

Q43556824-034AE754-ADAA-4EDF-A028-70907C694B63

Q43556824-04DAEFF8-202F-4144-9372-7AE8A32A5EEB

Q43556824-0FA92E63-221A-4D12-B14D-42AD51662CE4

Q43556824-112E4D1D-D5C8-4720-BC9E-0C8083157C0E

Q43556824-3BA04E2F-1F75-4A20-BA40-56047E55C8B1

Q43556824-468ADB70-6C6C-4227-8742-86D19EEF7447

Q43556824-4B05E2D7-2F9F-4579-A91B-037C55340372

Q43556824-924766B6-CA97-4A06-9291-9B0E85939BD5

Q43556824-E042D20E-1DE7-496C-8383-27A9FF42A815

Q43556824-E301E9F9-9AFA-419E-AEE0-6F0660DC6C18

P304

Q43556824-77D23536-B282-4E87-9587-E87ABC9B78D7

P31

Q43556824-5F21532D-17C5-4E70-A963-9DE3551520A3

P356

Q43556824-E5A6C8CD-D3FE-44C1-8612-9B5FEDD61959

P407

Q43556824-9251310E-4B8F-4165-B34E-A32C796A9BD8

P433

Q43556824-FE778B9E-2DBC-4B67-BD9B-E822C5EF27BA

P478

Q43556824-CA083390-7E14-4A44-AB34-7D11DCF541D4

P577

Q43556824-E7BC7031-8063-4F9B-8C9D-2733A0958497

P698

Q43556824-E767152E-3A81-4011-9CB8-400A78DBBEDD

P921

Q43556824-AD7A2D01-EF6F-45A6-8BD1-BB9E8D1BD9E4

P356

P1433

P1476

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.

@en

P2093

A V Swan

http://www.w3.org/2001/XMLSchema#string

A Weishaupt

http://www.w3.org/2001/XMLSchema#string

B Weissbrich

http://www.w3.org/2001/XMLSchema#string

D R Cornblath

http://www.w3.org/2001/XMLSchema#string

H Karch

http://www.w3.org/2001/XMLSchema#string

H P Hartung

http://www.w3.org/2001/XMLSchema#string

J Schubert

http://www.w3.org/2001/XMLSchema#string

J Zielasek

http://www.w3.org/2001/XMLSchema#string

K V Toyka

http://www.w3.org/2001/XMLSchema#string

Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

http://www.w3.org/2001/XMLSchema#string

P304

758-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.56.6.758

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11274311

http://www.w3.org/2001/XMLSchema#string

P921

Guillain–Barré Syndrome